Where the Money Comes From

Evelyn Marsh, 74, begins most Tuesdays the same way. Her aide arrives at 8:15. The remote blood pressure monitor on her nightstand logged her readings overnight and sent them to the care coordination platform her PCP adopted last year. Her prescriptions arrived Thursday by mail from a pharmacy-by-mail service her Medicare Part D plan uses. She has a telehealth appointment at 10 o’clock that she joins from her kitchen table on a tablet she got help learning to use at the library. By noon she has had more clinical contact than she would have managed in a full day of driving and waiting rooms three years ago.

Evelyn thinks of Tuesday mornings as things that work. She does not think about the five rooms where Tuesday morning was decided.

The aide arrives because a Medicaid LTSS waiver, funded jointly by the federal government and the state of Ohio, pays the agency that employs her. The remote monitoring device exists because the National Institutes of Health funded the clinical trials that validated it, and a subsequent CMS innovation grant paid for the pilot program that brought it to Evelyn’s care team. The telehealth platform was built with venture capital but is now expanding into the Medicare Advantage market with investment from institutional funds. The library where Evelyn learned to use the tablet receives federal funding through the Institute of Museum and Library Services and state appropriations that have been declining for a decade, supplemented by a local campaign the Friends of the Library ran in 2022. The mail pharmacy operates within a regulatory framework that Medicaid and Medicare have shaped for thirty years.

Five funding decisions made by five different institutions in five different rooms determined whether Evelyn’s Tuesday morning works. None of those rooms talked to each other about Evelyn. They did not need to. The decisions they made, separately and for their own reasons, compose into an ecosystem that Evelyn experiences as seamless.

The reader who understands where the money comes from can evaluate which parts of that ecosystem are durable and which are fragile.

The five capital sources that fund the transformation of aging at home are not a system. They are a sequence. Each one funds what the others cannot, and the order matters.

Government funding is the floor. Medicaid, Medicare, the BEAD broadband program, LIHEAP for energy assistance, the Weatherization Assistance Program, the workforce development funding that flows through the Department of Labor — these programs pay for the foundational infrastructure of aging at home. Medicaid funds approximately $880 billion in care services annually. Medicare funds the clinical visits, the durable medical equipment, the home health agency that employs Evelyn’s aide. Without government funding, the system does not exist at the scale that serves the broad population. The technology this publication has described can augment this infrastructure, but it cannot replace it.

Grants are ignition. The NIH grant that funded the clinical trial validating a remote monitoring protocol created the evidence that allowed CMS to reimburse for the service. The Robert Wood Johnson Foundation grant that funded a care coordination pilot in a rural health system produced the data that convinced an institutional investor to back the platform that scaled it. The CMS Innovation Center funds demonstration projects that, when successful, create the pathway for widespread Medicare coverage. Grants do not build lasting businesses or sustainable programs. They generate the evidence that unlocks larger capital. Without grants, the pipeline from research to clinical practice to market deployment does not function. The tools Evelyn uses this Tuesday exist because someone funded the proof ten years ago.

Institutional investors are the patient backbone. Pension funds, university endowments, insurance company investment portfolios, sovereign wealth funds — these are capital pools with time horizons measured in decades. They are not looking for a three-to-five-year exit. They are looking for durable returns over twenty-year periods, and aging infrastructure is beginning to look like a match for that time horizon. The 73 million Americans over 65 in 2030, the 80 million over 65 in 2040, represent a demographic demand curve that is not speculative. An institutional investor that backs aging-at-home infrastructure in 2026 is not betting on whether older adults will need home care. She is betting on the specific platforms, models, and operators that will serve a demand she can predict with high confidence.

Private equity is acceleration. The home care market fragmentation that makes individual agencies like Patrice’s locally excellent and systemically inefficient is exactly the condition PE consolidation is designed to address. PE-backed rollups can deploy care coordination technology at scale, negotiate with payers from a position of portfolio strength, and build the administrative infrastructure that individual agencies cannot afford. The extractive risk is real, as 17.01 documented. The scaling capacity is also real. The difference between PE that extracts and PE that builds depends on the fund’s time horizon, the operating expertise of its management teams, and the metrics it uses to measure performance. These are evaluable. They are not uniform.

Crowd and community investment is alignment. When a reader who has followed this publication for a year invests $1,000 in a Regulation CF crowdfunding round for an aging technology company, she is not primarily a financial investor. She is a person who has decided that the thing being built needs to exist, and who is expressing that conviction with money she can afford to lose. The financial return, if it comes, is secondary to the relationship: this woman is now a stakeholder in the infrastructure she depends on. Her interest as a user and her interest as an investor are the same interest. That alignment does not exist anywhere else in the capital structure.

The sequence matters because each stage unlocks the next.

Government funding creates the clinical and social infrastructure in which pilots are possible. Grants fund the pilots and generate the evidence. Evidence-backed clinical results convince institutional investors that the risk profile is manageable. Institutional investment brings scale and credibility that attracts PE attention. And the platform that has survived the sequence — government-funded infrastructure, grant-ignited innovation, institutionally backed scaling — can now open a crowdfunding round to the readers it has been serving, because those readers can see what has been built.

This is not a guaranteed sequence. Many good ideas die at the transition between grant funding and institutional investment because the evidence is not yet sufficient, or because institutional investors have not yet built the expertise to evaluate the category. The PE that enters before institutional capital has established the quality signal tends to be the extractive variety. The timing is not deterministic.

What the reader can do with this map is evaluate the funding stage of any aging technology company she encounters. A company funded entirely by grants may be producing excellent research without a path to scale. A company funded entirely by PE may be scaling without the clinical evidence base that grants generate. A company with institutional backing that is opening a Regulation CF round for individual investors is, structurally, in the position this series describes as best aligned with the reader’s interests: the sequence is functioning, and the company is inviting her to participate in what it has built.

Evelyn has not thought about any of this. She thinks about whether Sandra arrives on time, whether the blood pressure readings look different this week than last week, and whether the telehealth appointment will require her to figure out again where the mute button is. These are the right things to think about on a Tuesday morning.

But the reader who now understands the five rooms understands something Evelyn does not need to know on a Tuesday morning but may need to know when something changes. When the government room cuts Medicaid funding, Evelyn’s aide is at risk before Evelyn knows it. When the grant room stops funding clinical trials in her category, the evidence pipeline that would have brought new tools to her care team dries up. When institutional investors shift their attention to a different sector, the platform her PCP adopted may lose the funding that maintains it. When the PE room acquires her agency, the incentive structure shifts in ways that, by now, the reader can evaluate.

The reader who can trace Evelyn’s Tuesday morning back through five rooms is the reader who knows which rooms to watch.